一分钟看懂
这是一项关于Metastatic Malignant Solid Neoplasm的I 期研究，登记的药物或干预包括Biopsy Procedure；Biospecimen Collection；Computed Tomography；Echocardiography Test；Magnetic Resonance Imaging；Pidnarulex，当前状态为招募中。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biopsy Procedure；Biospecimen Collection；Computed Tomography；Echocardiography Test；Magnetic Resonance Imaging；Pidnarulex · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Cancer Institute Developmental Therapeutics Clinic · Bethesda
公开的入选条件
- * Patients must have histologically confirmed solid tumors with metastatic disease that have progressed after ≥ 1 line of prior therapy and/or for whom no standard treatment is available that has been shown to improve survival.
- * Patients must have a molecular testing report to assess HRD mutation status prior to enrollment.
- * Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, with at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesio
- * Patients must have a tumor site amenable to biopsy.
- * Age ≥ 18 years of age.
- * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥ 70%).
- * Absolute neutrophil count ≥ 1,500/mcL.
- * Hemoglobin ≥ 9 g/dL.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06606990；登记信息更新于 2026-09-16。